Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients' lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. Show more

188 East Blaine St., Suite 200, Washington, 98102, US

www.alpineimmunesciences.com

Pharmaceutical Preparation Manufacturing

Manufacturing

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$64.97

Open

$64.97

Volume

N/A

Day Range

$64.97 - $64.97

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

4.65%

Institutional Own.

99.47%

Qtr Updated

06/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Acazicolcept (ALPN-101) Details Systemic lupus erythematosus	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Povetacicept (ALPN-303) Details Autoimmune disease, Autoimmune nephritis, Immune complex membranoproliferative glomerulonephritis, IgA nephropathy	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Povetacicept (ALPN-303) Details Autoimmune disease, Systemic lupus erythematosus	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Povetacicept (ALPN-303) Details Autoimmune disease, Primary immune thrombocytopenia	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Davoceticept (ALPN-202) (CD28 costimulator) Details Advanced malignancies	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.